Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pancreatic Cancer Early Detection Consortium
Recruiting
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/23/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Overdiagnosis and Breast Cancer Screening Decisions
Recruiting
This is a survey-based study using an online panel. The goal of the study is to understand whether information about overdiagnosis influences breast cancer screening intention among older women. Participants are first asked a series of questions about breast cancer screening including their intention to continue screening, knowledge of screening, and beliefs about screening. They are then shown one of three videos about breast cancer screening that contain information about overdiagnosis or a fo... Read More
Gender:
FEMALE
Ages:
70 years and above
Trial Updated:
07/23/2025
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Mammography Screening, Geriatrics, Decision Aid
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/23/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Partial Epilepsy
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
Recruiting
The proposed study will use a randomized clinical trial design with non-equivalent control group and longitudinal design to evaluate the feasibility, acceptability, and preliminary effects of the Diabetes LIVE JustICE application. The design will incorporate repeated measures at 0, 6, and 12 weeks. Outcome variables will include recruitment assessments, participation, engagement, user experience, and measures proximally related to behavior change - e.g., diabetes knowledge, diabetes-related dist... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of Connecticut, Storrs Mansfield, Connecticut
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Recruiting
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: UConn Health-Farmington (University of Connecticut Health Center (UCHC)), Farmington, Connecticut
Conditions: Advanced Melanoma
QTX3034 in Patients With KRAS G12D Mutation
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Solid Tumors
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/22/2025
Locations: Connecticut Gastroenterology, Hartford, Connecticut
Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Recruiting
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Chase Medical Research, LLC, Waterbury, Connecticut
Conditions: Hypertension
Psychedelic Virtual Reality
Recruiting
The purpose of this study is to evaluate a novel VRP.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/22/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Psychedelic Experiences, Virtual Reality, Healthy Volunteer
Lung Transplant READY CF 2: A Multi-site RCT
Recruiting
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for consideration. Patient preference not to undergo lung transplant may account for 25-40% of decisions to defer referral. Rates of death without transplant are higher for people with CF who are members of marginal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Cystic Fibrosis
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
Recruiting
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155. This app is being developed to help people with schizophrenia manage their negative symptoms. The purpose of this study is to gather new information on CT-155. Researchers want to see how well it works, how well participants use the study app, and how it affects the use of health care services. Participants use the app for 16 weeks. They m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: CT Clinical Research, Cromwell, Connecticut
Conditions: Schizophrenia
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Yale Diabetes Research, New Haven, Connecticut
Conditions: Type 2 Diabetes